Follow
David Ridley
Title
Cited by
Cited by
Year
Developing drugs for developing countries
DB Ridley, HG Grabowski, JL Moe
Health Affairs 25 (2), 313-324, 2006
2532006
Entry and competition in generic biologics
HG Grabowski, DB Ridley, KA Schulman
Managerial and Decision Economics 28 (4‐5), 439-451, 2007
942007
Distance decreases with differentiation: Strategic agglomeration by retailers
GA Picone, DB Ridley, PA Zandbergen
International Journal of Industrial Organization 27 (3), 463-473, 2009
902009
Pharmaceutical followers
P Arcidiacono, PB Ellickson, P Landry, DB Ridley
International Journal of Industrial Organization 31 (5), 538-553, 2013
862013
Price differentiation and transparency in the global pharmaceutical marketplace
DB Ridley
Pharmacoeconomics 23, 651-658, 2005
682005
Would greater transparency and uniformity of health care prices benefit poor patients?
MK Kyle, DB Ridley
Health Affairs 26 (5), 1384-1391, 2007
662007
Herding versus Hotelling: Market entry with costly information
DB Ridley
Journal of Economics & Management Strategy 17 (3), 607-631, 2008
532008
The role of government reimbursement in drug shortages
A Yurukoglu, E Liebman, DB Ridley
American Economic Journal: Economic Policy 9 (2), 348-382, 2017
512017
The commercial market for priority review vouchers
DB Ridley, SA Régnier
Health Affairs 35 (5), 776-783, 2016
422016
Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases
DB Ridley, AC Sánchez
The Lancet 376 (9744), 922-927, 2010
362010
Impact of Medicaid preferred drug lists on therapeutic adherence
DB Ridley, KJ Axelsen
Pharmacoeconomics 24, 65-78, 2006
312006
Drugs and vaccines for developing countries
A Towse, E Keuffel, HE Kettler, DB Ridley
The Oxford handbook of the economics of the biopharmaceutical industry, 302-310, 2012
272012
Retail zoning and competition
DB Ridley, FA Sloan, Y Song
Working Paper, 2010
242010
Priorities for the priority review voucher
DB Ridley
The American journal of tropical medicine and hygiene 96 (1), 14, 2017
232017
No shot: US vaccine prices and shortages
DB Ridley, X Bei, EB Liebman
Health Affairs 35 (2), 235-241, 2016
232016
Strategic interaction among governments in the provision of a global public good
MK Kyle, DB Ridley, S Zhang
Journal of Public Economics 156, 185-199, 2017
182017
Forecasting market share in the US pharmaceutical market
S Regnier, DB Ridley
nature reviews drug discovery 14 (9), 594-595, 2015
182015
The cost of inefficiency in US hospitals, 1985-1997.
BR Shah, SD Reed, J Francis, DB Ridley, KA Schulman
Journal of Health Care Finance 30 (1), 1-9, 2003
182003
Priority review vouchers to encourage innovation for neglected diseases
HG Grabowski, DB Ridley, JL Moe
Prescribing cultures and pharmaceutical policy in the Asia-Pacific, 2009
172009
Spending on postapproval drug safety
DB Ridley, JM Kramer, HH Tilson, HG Grabowski, KA Schulman
Health Affairs 25 (2), 429-436, 2006
172006
The system can't perform the operation now. Try again later.
Articles 1–20